טוען...
Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect
Hepatocellular carcinoma (HCC) is a tumor that exhibits glucometabolic reprogramming, with a high incidence and poor prognosis. Usually, HCC is not discovered until an advanced stage. Sorafenib is almost the only drug that is effective at treating advanced HCC, and promising metabolism-related thera...
שמור ב:
| הוצא לאור ב: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7381782/ https://ncbi.nlm.nih.gov/pubmed/32765096 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S258196 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|